Reported by: Oahimire Omone Precious | Edited by: Oravbiere Osayomore Promise.
Scientists at Umeå University in Sweden, working with researchers from the United Kingdom and other international institutions, have developed an experimental antibody-based drug that has shown promising results in slowing the growth and spread of aggressive prostate cancer, raising hopes for a new treatment for one of the deadliest forms of the disease.
The findings were published in the peer-reviewed journal Signal Transduction and Targeted Therapy and focus on metastatic castration-resistant prostate cancer, the most advanced stage of the disease. This form of prostate cancer develops when cancer cells no longer respond to hormone therapy and spread to other parts of the body, making treatment significantly more difficult.
The research team developed a fully human monoclonal antibody designed to target a specific biological pathway that enables cancer cells to grow, invade surrounding tissues and spread throughout the body. Instead of attacking the cancer cells directly, the experimental treatment works by blocking the abnormal activation of transforming growth factor-beta receptor I (TβRI), a protein researchers identified as playing a major role in tumour progression and metastasis.
According to the scientists, cancer cells exploit this signalling pathway to become more aggressive and resistant to existing treatments. By preventing the receptor from undergoing a key molecular change, the experimental drug interrupts the chain of biological events that allows tumours to grow and spread to distant organs.
Professor Maréne Landström of Umeå University, who led the study, said the research was aimed at developing a treatment capable of preventing metastasis, which accounts for the vast majority of prostate cancer deaths. She explained that the team identified the biological mechanisms responsible for promoting cancer cell growth and spread, creating a potential new target for future therapies.
The researchers tested the antibody extensively in laboratory experiments and animal models of aggressive prostate cancer. The results showed that the treatment significantly reduced tumour growth and limited the spread of cancer cells. The experimental drug also demonstrated effectiveness comparable to docetaxel, one of the standard chemotherapy medicines used to treat advanced prostate cancer.
Unlike conventional chemotherapy, however, the new treatment produced no significant side effects during the preclinical studies, suggesting it may offer a safer and more targeted approach if future research confirms the findings in human patients.
The study also examined tumour samples from patients with advanced prostate cancer and found that elevated levels of the targeted receptor were associated with poorer survival outcomes. Researchers believe this discovery could help doctors identify patients most likely to benefit from the treatment if it eventually becomes available for clinical use.
Scientists highlighted another important advantage of the experimental therapy: its precision. Rather than interfering broadly with essential cellular processes, the antibody selectively blocks the cancer-promoting activity of the receptor while preserving its normal biological functions. This targeted approach could reduce unwanted side effects while improving treatment effectiveness.
Despite the encouraging results, the researchers cautioned that the drug remains in the experimental stage and has not yet been tested in human clinical trials. They emphasised that additional studies will be required to evaluate its safety, determine the appropriate dosage and confirm its effectiveness in people before it can be approved for routine medical use.
Prostate cancer remains one of the most commonly diagnosed cancers among men worldwide and is a leading cause of cancer-related deaths. While many patients respond well to surgery, radiation therapy and hormone treatment during the early stages of the disease, treatment options become far more limited once the cancer becomes resistant to therapy and spreads beyond the prostate.
Medical experts believe the discovery represents a significant advance in the search for more effective treatments for advanced prostate cancer. If future clinical trials validate the current findings, the experimental antibody could provide a new therapeutic option for patients with aggressive disease and improve survival prospects for thousands of men affected by metastatic prostate cancer each year.
📩 Stone Reporters News | 🌍 stonereportersnews.com
✉️ info@stonereportersnews.com | 📘 Facebook: Stone Reporters News | 🐦 X (Twitter): @StoneReportNew | 📸 Instagram: @stonereportersnews
Add comment
Comments